May 29th, 2022

A full text version of this article is available.
To access article obtain online access here or login
Proteomic Analyses of Recombinant Human Follicle-Stimulating Hormone and Urinary-Derived Gonadotropin Preparations
Authors:  Yoshimitsu Kuwabara, M.D., Ph.D., Katsuya Mine, M.D., Ph.D., Akira Katayama, Ph.D., Tomoko Inagawa, M.D., Shigeo Akira, M.D., Ph.D., and Toshiyuki Takeshita, M.D., Ph.D.
  OBJECTIVE: To understand the properties of each available gonadotropin preparation, especially in terms of the differences between urinary-derived and recombinant preparations.

STUDY DESIGN: Human menopausal gonadotropin (hMG), highly purified
urinary-derived follicle-
stimulating hormone (uFSH- HP) and recombinant FSH (rFSH) were subjected to 2-dimensional gel electrophoresis (2-DE), and protein spots were visualized by
silver-staining procedures. Major spots were analyzed by mass spectrometry.
Fluorescent-labeled preparations were also subjected to 2-DE to evaluate the quantities of FSH isohormones contained in each preparation.

RESULTS: 2-DE and mass spectrometry analyses of hMG identified many extracellular proteins as major impurities and several plasma membrane proteins including prion proteins. Both uFSH-HP and rFSH demonstrated slight impurities and showed several a and b subunit isohormones. rFSH contained higher amounts of the basic isohormones of the a subunit than uFSH-HP, whereas the predominance of the basic isohormones was less significant in the b subunit.

CONCLUSION: Proteomic analyses demonstrated the detailed protein profiles of each preparation. Differences in the quantities of a subunit isohormones may contribute to the variations in FSH activity observed between recombinant and urinary-derived FSH preparations. (J Reprod Med 2009;54: 459-466)
Keywords:  follicle-stimulating hormone, gonadotropin preparations, isohormone, proteomic analysis, prion protein
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from